Ocular Therapeutix (OCUL) Shares Outstanding (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Shares Outstanding (Entity) of $219.6 million for Q2 2026, up 26.98% year-over-year from $172.9 million in Q2 2025, and little changed on a QoQ basis from $218.9 million in Q1 2026.
Ocular Therapeutix (OCUL) Shares Outstanding (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Shares Outstanding (Entity) for 14 years, with the latest figure at $219.6 million in Q2 2026.
- Shares Outstanding (Entity) for Q2 2026 came in at $219.6 million, up 26.98% year-over-year; the trailing twelve-month figure through Jun 2026 was $219.6 million (up 26.98% YoY), and the FY2025 annual result was $215.9 million, up 36.88% from the prior year.
- Shares Outstanding (Entity) held at $219.6 million in Q2 2026, from $218.9 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $219.6 million in Q2 2026 and troughed at $76.8 million in Q1 2022.
- A 5-year average of $133.9 million and a median of $155.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest annual swing landed in 2022, when Shares Outstanding (Entity) climbed 0.53%; it then jumped 99.58% in 2024.
- A 5-year view of Shares Outstanding (Entity) shows it stood at $77.2 million in 2022, then gained by 3.4% to $79.8 million in 2023, then jumped by 97.61% to $157.7 million in 2024, then jumped by 36.88% to $215.9 million in 2025, then rose by 1.7% to $219.6 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $219.6 million in Q2 2026, $218.9 million in Q1 2026, and $215.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 224.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 224.95 Mn |
| Mar 31, 2026 | 224.10 Mn |
| Dec 31, 2025 | 187.24 Mn |
| Sep 30, 2025 | 183.92 Mn |
| Jun 30, 2025 | 172.59 Mn |
| Mar 31, 2025 | 169.40 Mn |
| Dec 31, 2024 | 158.27 Mn |
| Sep 30, 2024 | 166.99 Mn |
| Jun 30, 2024 | 165.82 Mn |
| Mar 31, 2024 | 132.02 Mn |
| Dec 31, 2023 | 79.83 Mn |
| Sep 30, 2023 | 79.37 Mn |
| Jun 30, 2023 | 78.05 Mn |
| Mar 31, 2023 | 77.39 Mn |
| Dec 31, 2022 | 76.88 Mn |
| Sep 30, 2022 | 76.98 Mn |
| Jun 30, 2022 | 76.76 Mn |
| Mar 31, 2022 | 76.75 Mn |
| Dec 31, 2021 | 76.39 Mn |
| Sep 30, 2021 | 76.55 Mn |